| 0 (0%) | 11-11 17:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.21 |
1-year : | 5.01 |
| Resists | First : | 3.61 |
Second : | 4.28 |
| Pivot price | 3.61 |
|||
| Supports | First : | 2.5 |
Second : | 2.08 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 3.61  |
| MA(100) : | 3.25 |
MA(250) : | 4.03 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 68.2 |
D(3) : | 68 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 9.93 | Low : | 1.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ METX ] has closed above bottom band by 5.7%. Bollinger Bands are 61.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.76 - 3.78 | 3.78 - 3.81 |
| Low: | 3.27 - 3.29 | 3.29 - 3.31 |
| Close: | 3.34 - 3.38 | 3.38 - 3.42 |
Thu, 16 Oct 2025
ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program - Business Wire
Mon, 29 Sep 2025
ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs - BioSpace
Fri, 26 Sep 2025
Canadian Investment Regulatory Organization Trade Resumption - METX - Barchart.com
Thu, 22 May 2025
ME Therapeutics Secures Investment to Advance R&D for Biotech Innovation - techcouver.com
Wed, 23 Apr 2025
Academic Programs and Departments - csuchico.edu
Mon, 13 May 2024
Mauritius hosts inaugural AI summit - UNESCO
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | 2.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 127.37 |
| Profit Margin | 64.9 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 0.8 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 7.96 |
| Sales Per Share | 53.33 |
| EBITDA (p.s.) | 23.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -214 (M) |
| Levered Free Cash Flow | -533 (M) |
| PE Ratio | 1.32 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0.06 |
| Price to Cash Flow | -0.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|